WELL TOLERABLE AND HIGHLY SPECIFIC ADAPTED RECOMBINASE FOR RECOMBINATION OF ASYMMETRIC TARGET REGIONS IN VARIETY OF STRAINS OF RETROVIRUSES Russian patent published in 2019 - IPC C12N9/22 C12N15/10 

FIELD: biotechnology.

SUBSTANCE: invention relates to the biotechnology. Described is a nucleic acid coding adapted recombinase, where the adapted recombinase is capable of recombining asymmetric target sequences of SEQ ID NO: 1 within a long end repeat of proviral DNA of multiple HIV-1 strains, wherein the amino acid sequence of the adapted recombinase has at least 95 % sequence identity with the sequence according to SEQ ID NO: 10, wherein said adapted recombinase contains certain amino acid substitutions compared to SEQ ID NO: 6: V7L, P12S, P15L, M30V, H40R, M44V, S51T, Y77H, K86N, Q89L, G93A, S108G, C155G, A175S, A249V, R259D, E262R, T268A, D278G, P307A, N317T, I320S. Described is an adapted recombinase encoded by the described nucleic acid, which is optionally expressed in the form of a fused protein. Presented is a transformed cell for treating or preventing HIV-1 infection containing the described nucleic acid. Described is a pharmaceutical composition for treating or preventing HIV-1 infection containing the described nucleic acid described by recombinase and/or presented transformed cell and pharmaceutically acceptable carrier(s), excipient(s) and/or adjuvant(s). Described is a method of producing said nucleic acid. Described is a method for preparing the described adapted recombinase.

EFFECT: invention enables producing well tolerated and highly specific adapted recombinase.

21 cl, 7 dwg, 6 ex